This may point to a fundamentally different involvement of microglia in pathological processes driven by amyloid-β or tau, but recent work from Sosna et al. (2018) also suggests that this might just be the result of the selected timing for treatment, since the early ablation of microglia in 5xTg-AD resulted in a reduction of soluble and insoluble forms of amyloid-β. The gene discussed is MAPT; the disease is Alzheimer disease.